Translational Science Symposium

Bridging the Valley of Death: Moving Technologies from the Lab to the Clinic

Wednesday, April 26, 2017  12:00 pm - 3:00 pm  Oregon Ballroom 201-202

12:00 pm  Opening Remarks
William Ju, MD and Patricia S. Walker, MD/PhD

Keynote Lecture
Introduction: Joseph Carroll, PhD

12:10 pm  Brian J. Druker, MD
Imatinib as a Paradigm of Targeted Cancer Therapies

Opening Lectures
Moderator: Patricia S. Walker, MD/PhD

12:35 pm  Joseph Carroll, PhD
Demystifying Tech Transfer

12:50 pm  Steven J. Prewitt
Creating Intellectual Property

1:05 pm  Real Life Stories
Moderator: William Ju, MD

Panelists:
R. Rox Anderson, MD
George Cotsarelis, MD
Richard Gallo, MD/PhD
Barbara Gilchrest, MD
Michael Girardi, MD
Aimee Payne, MD/PhD
Stuart Shanler, MD
David Woodley, MD

1:50 pm  Shark Tank: Making your Pitch: What do investors/partners look for when evaluating a University-based technology?
Moderator: Neal Walker, DO

Shark Tank Team #1
Shark Tank Team #2
Shark Tank Team #3

Panelists:
Frederick Beddingfield, MD/PhD
Joseph Carroll, PhD
John Doux, MD
William Ju, MD
Donna See
Patricia S. Walker, MD/PhD

Closing Lectures
Moderator: William Ju, MD

2:20 pm  Donna See
Unicorn Hunting: How do academic researchers begin?

2:35 pm  John Doux, MD
What Now?

2:50 pm  Concluding Remarks
William Ju, MD and Patricia S. Walker, MD/PhD

CONTINUED
CONTINUED:

Translational Science Symposium

Wednesday, April 26, 2017  12:00 pm – 3:00 pm  Oregon Ballroom  201-202

R. Rox Anderson, MD

Dr. Anderson graduated from MIT, and then received his MD degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology. After completing his dermatology residency and an NIH research fellowship at Harvard, he joined the faculty where he is now Harvard Medical School Professor in Dermatology, Director of the Wellman Center for Photomedicine; and adjunct Professor of Health Sciences and Technology at MIT. Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in medical care. Dr. Anderson’s research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions. In addition to research at the Wellman Center, he practices dermatology at Massachusetts General Hospital and teaches at Harvard and MIT. Dr. Anderson has been awarded over 60 national and international patents, and has co-authored over 250 scientific books and papers.

Frederick Beddingfield III, MD/PhD

Frederick Beddingfield III, MD/PhD is CEO of Sienna Biopharmaceuticals, Inc, a company focused on developing breakthrough products in aesthetics and dermatology. He is also a board-certified dermatologist and dermatologic surgeon. Dr. Beddingfield served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in October 2015. Prior to his appointment at Kythera, he held the role of Vice President and Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. Dr. Beddingfield led the development of premier products in the dermatology and aesthetics industry, including KYBELLA®, BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, and LATISSE®, all market-leading aesthetic treatments in their respective categories. During his tenure at Allergan, Dr. Beddingfield also led programs in acne, rosacea, scarring, hyperhidrosis, and hair loss. Dr. Beddingfield earned an MD Degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies.

Joseph Carroll, PhD

Dr. Carroll received his PhD in Molecular and Cellular Biology at SUNY-Stony Brook in 1992. He has a background in commercializing and translating genomic technologies in various disease settings. Over his 15 year career initiating and managing research efforts in biopharma and biotech, Dr. Carroll has held management positions in companies such as Genetics Institute, Wyeth, Millennium Pharmaceuticals, and Sirna Therapeutics. Dr. Carroll moved back to the academic sector in 2008 (Univ. of Colorado), and the Biomedical Diagnostics Inst (Dublin, Ireland) to facilitate greater academic-industry interactions. In his role managing business development for the Knight Cancer Institute, where he helps establish key alliances, partnerships and new ventures.

George Cotsarelis, MD

Dr. Cotsarelis received his B.A. and M.D. from the University of Pennsylvania, and did his dermatology residency at Penn. After a Dermatology Foundation Research award and a Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physician Scientists, he joined the faculty at Penn as an Assistant Professor of Dermatology in 1996. He was promoted to Full Professor in 2009, and then was appointed as Milton B Hartzell Professor of Dermatology and Chairman of the Department in 2010. Through his research on epithelial stem cells, Dr. Cotsarelis has impacted dermatology through the launching of the hair follicle stem cell field and his work resulted in understanding the pathogenesis of alopecias. The resulting work has showed that stem cells are destroyed in scarring alopecia, but are still retained in male pattern baldness.

John Doux, MD

John Doux is a board certified dermatologist. He obtained his B.S. degree and M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow. He completed an M.B.A. at the Wharton School of Business where he was a Palmer Scholar. Since 2004 he has served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare.

Brian J. Druker, MD

Dr. Druker is Director of the Knight Cancer Institute at Oregon Health & Science University (OHSU), JELD-WEN Chair of Leukemia Research, and an Investigator of the Howard Hughes Medical Institute. Upon graduating from the University of California, San Diego School of Medicine in 1981, Dr. Druker completed his internship and residency in internal medicine at Barnes Hospital, Washington School of Medicine in St. Louis, Missouri. He trained in oncology at Harvard’s Dana-Farber Cancer Institute and then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and its practical application to cancer therapies. Dr. Druker’s role in the development of imatinib and its application in the clinic has resulted in numerous awards for Dr. Druker, including the Warren Alpert Prize from Harvard Medical School, the 2009 Lasker-DeBakey Award for Clinical Medical Research, the Japan Prize in Healthcare and Medical Technology and the Albany Medical Center Prize in Medicine and Biomedical Research. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, the National Academy of Sciences in 2007, and the American Academy of Arts and Sciences in 2012.

Joseph Carroll, PhD

Dr. Carroll received his PhD in Molecular and Cellular Biology at SUNY-Stony Brook in 1992. He has a background in commercializing and translating genomic technologies in various disease settings. Over his 15 year career initiating and managing research efforts in biopharma and biotech, Dr. Carroll has held management positions in companies such as Genetics Institute, Wyeth, Millennium Pharmaceuticals, and Sirna Therapeutics. Dr. Carroll moved back to the academic sector in 2008 (Univ. of Colorado), and the Biomedical Diagnostics Inst (Dublin, Ireland) to facilitate greater academic-industry interactions. In his role managing business development for the Knight Cancer Institute, where he helps establish key alliances, partnerships and new ventures.

George Cotsarelis, MD

Dr. Cotsarelis received his B.A. and M.D. from the University of Pennsylvania, and did his dermatology residency at Penn. After a Dermatology Foundation Research award and a Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physician Scientists, he joined the faculty at Penn as an Assistant Professor of Dermatology in 1996. He was promoted to Full Professor in 2009, and then was appointed as Milton B Hartzell Professor of Dermatology and Chairman of the Department in 2010. Through his research on epithelial stem cells, Dr. Cotsarelis has impacted dermatology through the launching of the hair follicle stem cell field and his work resulted in understanding the pathogenesis of alopecias. The resulting work has showed that stem cells are destroyed in scarring alopecia, but are still retained in male pattern baldness.

John Doux, MD

John Doux is a board certified dermatologist. He obtained his B.S. degree and M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow. He completed an M.B.A. at the Wharton School of Business where he was a Palmer Scholar. Since 2004 he has served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare.

Brian J. Druker, MD

Dr. Druker is Director of the Knight Cancer Institute at Oregon Health & Science University (OHSU), JELD-WEN Chair of Leukemia Research, and an Investigator of the Howard Hughes Medical Institute. Upon graduating from the University of California, San Diego School of Medicine in 1981, Dr. Druker completed his internship and residency in internal medicine at Barnes Hospital, Washington School of Medicine in St. Louis, Missouri. He trained in oncology at Harvard’s Dana-Farber Cancer Institute and then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and its practical application to cancer therapies. Dr. Druker’s role in the development of imatinib and its application in the clinic has resulted in numerous awards for Dr. Druker, including the Warren Alpert Prize from Harvard Medical School, the 2009 Lasker-DeBakey Award for Clinical Medical Research, the Japan Prize in Healthcare and Medical Technology and the Albany Medical Center Prize in Medicine and Biomedical Research. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, the National Academy of Sciences in 2007, and the American Academy of Arts and Sciences in 2012.

CONTINUED
CONTINUED:
Translational Science Symposium

Wednesday, April 26, 2017 12:00 pm – 3:00 pm Oregon Ballroom 201-202

Richard L. Gallo, MD/PhD
Richard L. Gallo, MD/PhD, is Professor of Medicine and Pediatrics, and Chair for the Department of Dermatology at the University of California, San Diego. His research focuses on the role of the innate immune system in skin health and disease, focusing on antimicrobial peptides and aspects of the basic functions of the skin immune system. He has contributed several landmark observations to the field of Dermatology including the first description of an antimicrobial peptide in mammalian skin, the first demonstration that mammals depend on antimicrobial peptides for defense against infection, and the first association of a human diseases (atopic eczema and Rosacea) with a defect in antimicrobial peptide production. His work has been seen in some of the most prestigious scientific and medical journals and is well supported by grants from the NIH, the Veterans Administration, and private foundations. Dr. Gallo trained in Dermatology at Harvard Medical School where he also completed a post-doctoral fellowship in Cell and Developmental Biology. He received his MD degree at the University of Rochester, where he also received his PhD in Radiation Biology and Biophysics. Prior to Dermatology Dr. Gallo trained in Pediatrics at Johns Hopkins Hospital.

Barbara Gilchrest, MD
Barbara A. Gilchrest, M.D., received her undergraduate and medical training from the Massachusetts Institute of Technology (MIT) and Harvard Medical School (HMS) respectively. After a post-doctoral fellowship in the laboratory of Howard Green at MIT, in 1977 Dr. Gilchrest joined the Department of Dermatology and Division on Aging at the HMS. From 1985 until 2008, Dr. Gilchrest served as Professor and Chairman of Dermatology at the Boston University School of Medicine, where she directed a large laboratory and an NIH-sponsored post-doctoral research training program. In 2015 she joined the Department of Dermatology at the Massachusetts General Hospital and HMS. She has served in leadership positions for all the major dermatologic organizations; on the National Advisory Council on Aging and the Board of Scientific Counselors of the National Cancer Institute; the Editor of the Journal of Investigative Dermatology, as Associate Editor or editorial board member of several other major clinical and research journals; as a consultant or scientific advisory board member for pharmaceutical and biotechnology companies; and as a member of the MIT Corporation (1995-2005). Dr. Gilchrest is a Fellow of the American Association for the Advancement of Science, an elected member of the National Academy of Medicine, and a Charter member of the National Academy of Inventors.

Michael Girardi, MD
Dr. Girardi is Professor, Vice Chair, and the Residency Program Director for the Department of Dermatology of the Yale School of Medicine. Dr. Girardi graduated magna cum laude with degrees in Biology and Computer Science from Brown University, and from the Yale School of Medicine with the Honors. He has a broad research experience in cutaneous carcinogenesis and cutaneous immunology, funded by the National Cancer Institute for more than 15 years. His laboratory is credited with major contributions to our understanding of cutaneous immunoregulation of skin cancer, including the relative contributions of gamma-delta T cells, NKG2D ligands, innate lymphoid cells, Langerhans cells, and genetic drivers of cutaneous lymphoma. Dr. Girardi has served as the Co-Director for the Yale Comprehensive Cancer Center’s Immunology and Immunotherapy Program, and is currently the Director of the Photopheresis and Phototherapy Unit. Dr. Girardi is holder of 4 biomedical patents on skin delivery of therapeutics including novel strategies for skin cancer prevention and treatment, and the efficient and global activation of monocytes for immunotherapy.

William Ju, MD
Dr. Ju is a board-certified dermatologist with over 20 years of experience in the biopharmaceutical industry within a wide variety of therapeutic areas (including dermatology), and in a broad range of entities at different stages of organizational development. This includes leadership positions in business startups to Fortune 100 companies and in nonprofits. Dr. Ju is currently President and a founding trustee of Advancing Innovation in Dermatology, Inc.

Aimee Payne, MD/PhD
Dr. Payne is an Albert M. Kligman Associate Professor of Dermatology at University of Pennsylvania. She obtained her BS in Biology from Stanford University and received her MD/PhD (Molecular and Cellular Biology) Degrees from Washington University School of Medicine in St. Louis. Her career interest has been in pemphigus: diagnosing and treating patients with this potentially fatal autoimmune disease, and performing research to understand what causes disease, with the goal of improving therapy. Her laboratory has contributed to 5 major areas of investigation: 1) cloning and characterization of B-cell repertoires to understand how autoimmunity occurs in pemphigus, a model autoantibody-mediated skin blistering disease; 2) cell biologic studies to understand mechanisms for loss of cell adhesion; 3) collaborative research to advance clinical trials in autoimmune blistering disease; 4) clinical studies to better understand current diagnostic tests and therapies; and 5) translational research to develop novel targeted therapies. In addition to her research activities, she is a board certified dermatologist with a special focus on autoimmune blistering skin diseases.

CONTINUED
CONTINUED:

Translational Science Symposium

Wednesday, April 26, 2017       12:00 pm – 3:00 pm Oregon Ballroom  201-202

Steven J. Prewitt

Steven Prewitt is Schwabe's Intellectual Property Service Group Leader and a member of the firm's Technology Industry Group. He guides companies and research institutions through the technology development, protection, commercialization and enforcement life cycle to maximize the value of their intellectual property. Having drafted and prosecuted over 500 utility and design patent applications in more than 17 years of practice, Mr. Prewitt has a deep understanding of the value of technology as a critical business asset, and what it takes to effectively protect that asset. He has a diverse technical background, which includes biotechnology, medical devices, mechanical devices, and software technology. He holds a B.A. in Biology from the University of Virginia and a J.D. from George Mason University School of Law.

Donna See

Donna has over 15 years of experience in technology commercialization, as an investor, founder, and advisor to dozens of start-ups in the life sciences and technology sectors. Donna is currently a Vice President at Allied Minds, a publicly-traded venture capital firm, and Vice President of Allied-Bristol Life Sciences, a joint venture between Allied Minds and Bristol-Myers Squibb. She leads Allied Minds’ pipeline development, overseeing scouting, diligence, and founding of new ventures based on intellectual property created by Allied Minds’ network of over 160 university and federal lab partners. She currently serves as an advisor, mentor, or reviewer to technology development and translational funds at several universities, including the University of California at Davis, University of Southern California, Emory University, Georgia Tech, Columbia University, and the University of Michigan. Donna previously served as the Director of Licensing and Director of Strategic Initiatives for Columbia Technology Ventures, an internationally-recognized leader in the field of university tech transfer. Prior to Columbia, Donna was a Director of Business Development and Technology Transfer at New York-Presbyterian Hospital, forging strategic alliances with government and industry partners to evaluate, develop, and adopt healthcare innovations. She also spent over a decade in global and domestic public health, working with the World Bank, Centers for Disease Control, and other public and private sector organizations to improve health care access, delivery, and quality. Donna received her MBA from Columbia Business School and her MPH in Health Policy & Management from Columbia University’s School of Public Health. She holds a BA in the Natural Sciences from The Johns Hopkins University.

Stuart Shanler, MD

Stuart D. Shanler, M.D. co-founded Aclaris Therapeutics, Inc. and has served as their Chief Scientific Officer since their inception in July 2012. Between July 2011 and July 2012, Dr. Shanler co-invented a topical rosacea drug for, and co-founded and served as Chief Scientific Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Shanler was a dermatologic surgeon in private practice. Dr. Shanler is a board-certified dermatologist and received his M.D. degree from Albany Medical College of Union University and received B.S. degrees in Biology and the Biological Basis of Behavior from the University of Pennsylvania.

Neal Walker, DO

Dr. Walker is a board certified dermatologist and serial entrepreneur with over 18 years of experience in the pharmaceutical industry. He served as a consultant to a number of pharmaceutical companies, co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan. Previously, Dr. Walker co-founded and led a number of life science companies including Octagon Research Solutions, Trigenesis Therapeutics, and Cutix.

Patricia S. Walker, MD/PhD

Dr. Walker is a Board-Certified Dermatologist and Pharmaceutical industry expert specializing in the fields of medical and aesthetic dermatology. Dr. Walker previously served as Chief Medical Officer of Kythera Biopharmaceuticals, Inc. and also was Executive Vice President and Chief Science Officer at Allergan Medical. From 1997 to 2004, Dr. Walker held positions at Allergan Inc. where she ultimately served as Vice President, Clinical Research and Development for skin care pharmaceuticals. Over the past 10 years, Dr. Walker was involved in key product approvals in dermatology and aesthetic medicine including the development and approval of Tazorac®, Azelix®, Avage®, BOTOX® Cosmetic, Hylaform®, Captique®, JUVÉDERM®, Biocentrics®, LAP-BAND® and Inamed® Silicone gel-filled Breast Implants, and Kybella. Dr. Walker received an M.D. and a PhD in Physiology and Biophysics from the University of Iowa. Dr. Walker completed a residency in Dermatology and a research fellowship in the Dermatology Branch, National Cancer Institute at the National Institute of Health. Dr. Walker also maintains a private practice.

David Woodley, MD

Dr. Woodley completed his undergraduate degree in English Literature at Washington University in St. Louis and his medical school education at the University of Missouri in Columbia, Missouri. He completed his dermatology residency training at the University of North Carolina in Chapel Hill, North Carolina. He left Chapel Hill in 1989 to be Professor and Associate Chair of the Department of Dermatology at Stanford University. In 1992, he was appointed the Walter Hemin Professor and Chair of Dermatology at Northwestern University. In 1999, he joined the medical faculty at the Keck School of Medicine of the University of Southern California (USC) and in 2004, he was named as the Founding Chair of the USC Department of Dermatology. He is the author of over 200 original articles and is a clinician-investigator with continuous NIH funding since 1992.